Janssen Pharmaceutical

• NCT04062448

  Phase 2, Completed, 16 people, 20 Aug 2019

• NCT03474679

  Phase 3, Completed, 19 people, 22 Mar 2018

• NCT02918331

  Phase 1, Completed, 7 people, 28 Sept 2016

• NCT02556892

  Phase 1, Completed, 8 people, 22 Sept 2015

• NCT02530060

  Phase 4, Completed, 8 people, 20 Aug 2015

• NCT02497378

  Phase 1, Completed, 8 people, 14 Jul 2015

• NCT02405858

  Phase 4, Completed, 51 people, 1 Apr 2015

• NCT02169180

  Phase 2, Completed, 16 people, 23 Jun 2014

• NCT01309386

  Phase 3, Completed, 100 people, 7 Mar 2011

• NCT00985959

  Phase 1, Completed, 101 people, 29 Sept 2009

• NCT00796003

  Phase 1, Completed, 39 people, 24 Nov 2008

• NCT00737048

  Phase 3, Completed, 328 people, 18 Aug 2008

• NCT00736957

  Phase 3, Completed, 219 people, 18 Aug 2008

• NCT00736853

  Phase 3, Completed, 321 people, 18 Aug 2008

• NCT00727987

  Phase 3, Completed, 269 people, 5 Aug 2008

• NCT00396565

  Phase 3, Completed, 394 people, 7 Nov 2006

• NCT00216645

  Phase 2, Completed, 74 people, 22 Sept 2005

• Refining the simplified frailty scale to improve the risk stratification of patients with multiple myeloma

  Fees or honoraria, Grants or research support, 29 Aug 2026

• Associations of Hearing Loss Defined by Updated World Health Organization Criteria With Socioeconomic Status and Health Check-Up-Related Factors: A Population-Based Cross-Sectional Study in Japan

  Fees or honoraria, 1 Aug 2026

• Prognostic Impact of Combined Nutritional and Cognitive Status on Long-Term Outcome in Acute Decompensated Heart Failure

  Fees or honoraria, 6 Jan 2026

• Sarcopenia-related gut microbiota in the elderly: Insights from the longevity region of Kyotango and its nutritional associations

  Fees or honoraria, 9 Dec 2025

Sources: pubmed.ncbi.nlm.nih.gov